Abstract:Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and leads to ~10,000 deaths each year. Nifurtimox and benznidazole are the only two drugs available but have significant adverse effects and limited efficacy. New chemotherapeutic agents are urgently required. Here we identified inhibitors of the acidic M17 leucyl-aminopeptidase from T . cruzi (LAPTc) that show promise as novel starting points for Chagas disease drug discovery. A RapidFire-MS screen with a protease-focused compound library identified novel LAPTc inhibitors. Twenty-eight hits were progressed to the dose-response studies, from which 12 molecules inhibited LAPTc with IC 50 < 34 μM. Of these, compound 4 was the most potent hit and mode of inhibition studies indicate that compound 4 is a competitive LAPTc inhibitor, with K i 0.27 μM. Compound 4 is selective with respect to human LAP3, showing a selectivity index of >500. Compound 4 exhibited sub-micromolar activity against intracellular T . cruzi amastigotes, and while the selectivity-window against the host cells was narrow, no toxicity was observed for un-infected HepG2 cells. In silico modelling of the LAPTc-compound 4 interaction is consistent with the competitive mode of inhibition. Molecular dynamics simulations reproduce the experimental binding strength (-8.95 kcal/mol), and indicate a binding mode based mainly on hydrophobic interactions with active site residues without metal cation coordination. Our data indicates that these new LAPTc inhibitors should be considered for further development as antiparasitic agents for the treatment of Chagas disease. Trypanosoma cruzi is a single cell eukaryotic parasite that infects humans and animals. Infection can result in Chagas disease, a debilitating chronic disease that frequently affects the heart. The major downside of the current treatments is their side-effects, which frequently prevent patients from completing their treatment course. New, safer medicines are therefore urgently needed. Here we sought to enable the development of new medicines by identifying inhibitors of a key parasite enzyme; acidic M17 leucyl-aminopeptidase (LAPTc). We identified 28 LAPTc inhibitors, among more than 3000 compounds tested. The most potent inhibitor, compound 4, inhibited parasite growth and did not inhibit the equivalent human aminopeptidase. Using computational tools, we predicted how this compound binds to the enzyme. Our results indicate that the LAPTc inhibitors could be considered for further development as antiparasitic agents for the treatment of Chagas disease.

Validation of Trypanosoma cruzi inactivation techniques for laboratory use

Acrylonitrile Derivatives against Trypanosoma cruzi: In Vitro Activity and Programmed Cell Death Study

E-Cyanoacrylamides and 5-Imino Pyrrolones against Trypanosoma cruzi: Activity and Induced Mechanisms of Cell Death

Dissecting the interstrand crosslink DNA repair system of Trypanosoma cruzi

Serial ‘deep-sampling’ PCR of fragmented DNA reveals the wide range of Trypanosoma cruzi burden among chronically infected hosts and allows accurate monitoring of parasite load following treatment

Evaluation of the in vivo therapeutic properties of (-)-cubebin and (-)-hinokinin against Trypanosoma cruzi

High Throughput Screening for Anti–Trypanosoma cruzi Drug Discovery

A Computational Approach Using α-Carbonic Anhydrase to Find Anti-Trypanosoma cruzi Agents

Identification of a potent and selective LAPTc inhibitor by RapidFire-Mass Spectrometry, with antichagasic activity

TropD-Detector: A CRISPR/LbCas12a-Based system for rapid and sensitive screening of Trypanosoma cruzi in Chagas vectors and reservoirs

Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease

Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' Disease

Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies

Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease

Discovery of Strong 3-Nitro-2-Phenyl- 2H-Chromene Analogues as Antitrypanosomal Agents and Inhibitors of Trypanosoma cruzi Glucokinase

Vaccination with parasite-specific TcTASV proteins combined with recombinant baculovirus as a delivery platform protects against acute and chronic Trypanosoma cruzi infection

Characterization of Novel Trypanosoma cruzi-Specific Antigen with Potential Use in the Diagnosis of Chagas Disease

Loop-Mediated Isothermal Amplification of Trypanosoma cruzi DNA for Point-of-Care Follow-Up of Anti-Parasitic Treatment of Chagas Disease

Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds Inhibiting Putrescine Uptake

Impact of gastrointestinal inoculation and benznidazole treatment on infection by Trypanosoma cruzi (Y strain, DTU TcII) in Swiss mice

Lab on a chip (LOC) platform for drug screening against the intracellular forms of Trypanosoma cruzi